Clinical trialPhase 2Terminated
Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E Mutation
- Outcome
- Stopped early. Results posted; single-arm, no comparisonSlow accrual (Enrollment)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 16 November 2020
- Ended
- 1 November 2023
- Enrollment
- 6 participants
- Sites
- 5
- Primary outcomes
- Objective Response Rate (ORR) at 24 Weeks
- Sponsor type
- Academic / other
- Results posted
- 23 January 2024
- Last update
- 6 May 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 6 May 2024
- ORR
- Objective Response Rate (ORR) at 24 WeeksTreatment (Encorafenib, Binimetinib): 33.33 (4.33 to 77.72), n = 6Values: percentage of patients, 95% Confidence IntervalTime frame: 24 weeksNo analysis posted for this outcome (outcome 1)
- Participants
- Treatment (Encorafenib, Binimetinib): 6 started, 0 completed
- Serious adverse events
- Treatment (Encorafenib, Binimetinib): 1 of 6Participants with at least one serious adverse event, of those at risk, as posted
5 secondary outcomes
- PFS · Progression-free Survival (PFS)
- Treatment (Encorafenib, Binimetinib) 7.1 (1.7 to NA), n=6 [median months, 95% Confidence Interval]
- OS · Overall Survival
- Treatment (Encorafenib, Binimetinib) 15.0 (3.1 to NA), n=6 [median months, 95% Confidence Interval]
- Duration of Response
- Treatment (Encorafenib, Binimetinib) 9.9 (8.5 to NA), n=3 [median months, 95% Confidence Interval]
- Time to Response
- Treatment (Encorafenib, Binimetinib) 3.9 (3.6 to NA), n=6 [median months, 95% Confidence Interval]
- Number of Patients With Grade 3+ Adverse Events
- Treatment (Encorafenib, Binimetinib) 3/6 [Participants]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This phase II trial studies the side effects and how well the combination of binimetinib and encorafenib work in treating patients with pancreatic cancer with a somatic BRAF V600E mutation. Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and encorafenib may work better compared to the usual treatment in treating patients with pancreatic cancer and a somatic BRAF V600E mutation.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVE: I. To determine the efficacy of the combination of binimetinib and encorafenib as \>= 2nd line of treatment for patients with metastatic pancreatic cancer with BRAF V600E mutation. SECONDARY OBJECTIVES: I. To determine in patients treated with the combination of binimetinib and encorafenib as \>= 2nd line of treatment for patients with metastatic pancreatic cancer with BRAF V600E mutation: Ia. The median progression-free survival. Ib. The median overall survival. Ic. Duration of response. Id. Time to response. Ie. The safety and tolerability. OUTLINE: Patients receive encorafenib orally (PO) once daily (QD) and binimetinib PO twice daily (BID) on days 1-25. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for up to 5 years.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Objective Response Rate (ORR) at 24 Weeks [24 weeks]. Number, percentage of patients (95% Confidence Interval). Treatment (Encorafenib, Binimetinib) (n=6): 33.33 (4.33 to 77.72).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-free Survival (PFS) [25 months]. Median, months (95% Confidence Interval). Treatment (Encorafenib, Binimetinib) (n=6): 7.1 (1.7 to NA) [The upper limit of the confidence interval was not estimatable due to an insufficient number of participants with events].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival [25 months]. Median, months (95% Confidence Interval). Treatment (Encorafenib, Binimetinib) (n=6): 15.0 (3.1 to NA) [The upper limit of the confidence interval was not estimatable due to an insufficient number of participants with events].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Duration of Response [12 months]. Median, months (95% Confidence Interval). Treatment (Encorafenib, Binimetinib) (n=3): 9.9 (8.5 to NA) [The upper limit of the confidence interval was not estimatable due to an insufficient number of participants with events].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Time to Response [25 months]. Median, months (95% Confidence Interval). Treatment (Encorafenib, Binimetinib) (n=6): 3.9 (3.6 to NA) [The upper limit of the confidence interval was not estimatable due to an insufficient number of participants with events].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Patients With Grade 3+ Adverse Events [25 months]. Count Of Participants, Participants. Treatment (Encorafenib, Binimetinib) (n=6): 3.